Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 2:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,208 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Oral Tumors Clear all
Terminated Phase 1Phase 2 Interventional Results available

Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma

NCT01881789
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Oprozomib, Lenalidomide, Dexamethasone, Cyclophosphamide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
14
States / cities
Huntsville, Alabama • Burbank, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Jun 27, 2026, 2:24 AM EDT
Recruiting Phase 1 Interventional

How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers

NCT07444268
View directory record Official record
Conditions
Advanced Hematologic Malignancies
Interventions
DSP-5336, [14C]-DSP-5336
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jun 27, 2026, 2:24 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

NCT04161391
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation, Metastatic Solid Tumor, Advanced Solid Tumor
Interventions
TPX-0046
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
20
States / cities
La Jolla, California • Orange, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Jun 27, 2026, 2:24 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma

NCT00301418
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
Erlotinib
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Jun 27, 2026, 2:24 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Interventions
Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
13
States / cities
Denver, Colorado • Fort Myers, Florida • Tallahassee, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 27, 2026, 2:24 AM EDT
Completed Phase 1 Interventional

A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors

NCT01106508
View directory record Official record
Conditions
Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma, Locally Advanced or Metastatic Basal Cell Carcinoma
Interventions
LEQ506
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Jun 27, 2026, 2:24 AM EDT
Terminated No phase listed Observational

Smartphone Pain App for Assessing Oral Mucositis Pain in Patients

NCT02727062
View directory record Official record
Conditions
Oral Mucositis
Interventions
OM Pain App, Accelerometer
Device
Lead sponsor
Stuart Wong
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Jun 27, 2026, 2:24 AM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.

NCT00399659
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Timeline
2006 – 2007
U.S. locations
57
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Jun 27, 2026, 2:24 AM EDT
Completed Phase 1 Interventional

Sunitinib in Treating Young Patients With Refractory Solid Tumors

NCT00387920
View directory record Official record
Conditions
Central Nervous System Metastases, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Recurrent Childhood Central Nervous System Embryonal Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
sunitinib malate, pharmacological study, dynamic contrast-enhanced magnetic resonance imaging, laboratory biomarker analysis
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
15
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Jun 27, 2026, 2:24 AM EDT
Recruiting Not applicable Interventional

F.L.O.S.S. Project (Facilitated Lessons on Oral and Systemic Health in Survivors)

NCT06315855
View directory record Official record
Conditions
Oral Mucositis, Periodontal Diseases, Cancer
Interventions
Telehealth Intervention (THI)
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
25 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jun 27, 2026, 2:24 AM EDT
Suspended Phase 1 Interventional

Study of XL418 in Adults With Solid Tumors

NCT00460278
View directory record Official record
Conditions
Cancer, Solid Tumors
Interventions
XL418
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
2
States / cities
Detroit, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2008 · Synced Jun 27, 2026, 2:24 AM EDT
Completed Phase 1 Interventional

A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas

NCT01588678
View directory record Official record
Conditions
Advanced Solid Tumor, Lymphoma
Interventions
DS-3078a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Jun 27, 2026, 2:24 AM EDT
Recruiting Phase 4 Interventional

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

NCT06562543
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Fruquintinib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
44
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 27, 2026, 2:24 AM EDT
Terminated Phase 2 Interventional

Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

NCT02638909
View directory record Official record
Conditions
Colorectal Adenocarcinoma, Cholangiocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma
Interventions
ceritinib
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2018 · Synced Jun 27, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer

NCT00069121
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Capecitabine, Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
48
States / cities
Mobile, Alabama • Alhambra, California • Bakersfield, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Jun 27, 2026, 2:24 AM EDT
Completed Phase 1 Interventional

Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors

NCT02324621
View directory record Official record
Conditions
Unspecified Adult Solid Tumor
Interventions
Oral ONC201, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Jun 27, 2026, 2:24 AM EDT
Completed Phase 2 Interventional

Vinorelbine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00008333
View directory record Official record
Conditions
Lung Cancer
Interventions
vinorelbine tartrate
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
65 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
13
States / cities
Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jun 27, 2026, 2:24 AM EDT
Completed Phase 1 Interventional

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

NCT00004065
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
tanespimycin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Jun 27, 2026, 2:24 AM EDT
Completed No phase listed Observational

Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium

NCT01321892
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Larynx, Hypopharynx
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Jun 27, 2026, 2:24 AM EDT
Active, not recruiting Phase 1 Interventional

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

NCT03875287
View directory record Official record
Conditions
Solid Tumor
Interventions
Decitabine, Cedazuridine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jun 27, 2026, 2:24 AM EDT
Completed Phase 1Phase 2 Interventional

Procarbazine in Treating Patients With Recurrent Brain Tumor

NCT00004004
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
procarbazine hydrochloride
Drug
Lead sponsor
New Approaches to Brain Tumor Therapy Consortium
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
10
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Jun 27, 2026, 2:24 AM EDT
Recruiting Phase 1Phase 2 Interventional

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

NCT07558733
View directory record Official record
Conditions
HR+ HER2- Breast Cancer
Interventions
Serabelisib, Sapanisertib, Fulvestrant
Drug
Lead sponsor
Faeth Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
3
States / cities
Los Angeles, California • Springfield, Oregon • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jun 27, 2026, 2:24 AM EDT
Completed Phase 1Phase 2 Interventional

A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer

NCT01073384
View directory record Official record
Conditions
Enteritis
Interventions
SGX201 (delayed release beclomethasone 17,21-dipropionate)
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Jun 27, 2026, 2:24 AM EDT
Completed Phase 1 Interventional

A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer

NCT02507544
View directory record Official record
Conditions
Carcinoma, Advanced Cancer
Interventions
TRX-818 capsules
Drug
Lead sponsor
TaiRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Grand Rapids, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Jun 27, 2026, 2:24 AM EDT